Literature DB >> 1662627

Effects of environmental factors on the in vitro potency of azithromycin.

J A Retsema1, L A Brennan, A E Girard.   

Abstract

The effects of media, pH, cations, serum, CO2 or anaerobic atmosphere, inoculum size and time of incubation on the in vitro potency of azithromycin were determined. The potency of azithromycin against all genera was particularly sensitive to changes in pH. The MIC for Staphylococcus aureus strains ranged from 50 micrograms/ml at pH 6 to less than or equal to 0.025 micrograms/ml at pH 8; for erythromycin the MIC change was less (1.6 to 0.05 micrograms/ml). Incubation for 18 h in 5% CO2 or an anaerobic atmosphere (10% CO2, 10% H2, 80% N2) lowered the pH by approximately 0.8 units with gram-negative organisms and 0.4 units with gram-positive organisms. This resulted in an MIC eight times greater than the aerobic MIC. In addition, the MIC100 for azithromycin and erythromycin against Bacteroides strains growing in Wilkins-Chalgren broth fell from 3.1 micrograms/ml in the anaerobic atmosphere to 0.2 and 0.4 micrograms/ml, respectively, when using the Oxyrase enzyme system to remove oxygen. With the Oxyrase system, the pH of the medium at the MIC remained at 7.2, while it fell to 6.7 in the anaerobic gas mixture. An increase in potency for both agents was also observed with other anaerobic species when using the Oxyrase system. The addition of serum produced an increase in potency of azithromycin and erythromycin that correlated with an increase in pH during incubation, despite the use of buffered media. Adding cations to Mueller-Hinton broth resulted in increased MICs for gram-negative organisms; the highest increases observed were four-fold for Escherichia coli.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662627     DOI: 10.1007/bf01975836

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

1.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

2.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria.

Authors:  M D Kitzis; F W Goldstein; M Miégi; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Comparison of the acid stability of azithromycin and erythromycin A.

Authors:  E F Fiese; S H Steffen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo.

Authors:  J A Retsema; A E Girard; D Girard; W B Milisen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

8.  Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa.

Authors:  R E Hancock; V J Raffle; T I Nicas
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

9.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more
  13 in total

1.  Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.

Authors:  Peter J Petersen; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.

Authors:  P D Midolo; J D Turnidge; J R Lambert; J M Bell
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.

Authors:  L M Ednie; S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.

Authors:  S Hunt Gerardo; D M Citron; M C Claros; E J Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Determination of In Vitro Activities of Solithromycin at Different pHs and Its Intracellular Activity against Clinical Isolates of Neisseria gonorrhoeae from a Laboratory Collection.

Authors:  Julia Mallegol; Prabhavathi Fernandes; Christine Seah; Cyril Guyard; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

6.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.

Authors:  R S Witzig; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium.

Authors:  I Herrera-Insúa; K Jacques-Palaz; B E Murray; R M Rakita
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine.

Authors:  S T Brown; F F Edwards; E M Bernard; W Tong; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Oxyrase, a method which avoids CO2 in the incubation atmosphere for anaerobic susceptibility testing of antibiotics affected by CO2.

Authors:  S K Spangler; P C Appelbaum
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.